Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefextinib in advanced solid tumors
NCT04183764Phase 1Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nefextinib in solid tumor, sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Maximum tolerated dose at 4 weeks, Adverse events at 8 weeks and 1 more. Status: unknown.
02
Drugs
nefextinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04183764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183764.